Vericel Co. (NASDAQ:VCEL) Insider Sells $242,256.92 in Stock

Vericel Co. (NASDAQ:VCEL - Get Free Report) insider Jonathan Siegal sold 3,908 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the transaction, the insider now directly owns 1,206 shares in the company, valued at $74,759.94. The trade was a 76.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vericel Trading Up 0.9 %

Shares of Vericel stock traded up $0.52 during trading on Monday, reaching $59.06. The stock had a trading volume of 257,291 shares, compared to its average volume of 427,304. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 984.50 and a beta of 1.72. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $61.99. The stock has a fifty day moving average price of $57.69 and a two-hundred day moving average price of $50.86.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. On average, equities analysts forecast that Vericel Co. will post 0.14 EPS for the current fiscal year.

Institutional Trading of Vericel

Several institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its stake in Vericel by 3.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 661,018 shares of the biotechnology company's stock valued at $30,329,000 after acquiring an additional 19,803 shares during the period. Sei Investments Co. increased its position in Vericel by 25.9% during the second quarter. Sei Investments Co. now owns 62,139 shares of the biotechnology company's stock worth $2,851,000 after acquiring an additional 12,799 shares during the period. Squarepoint Ops LLC acquired a new stake in Vericel in the 2nd quarter worth about $513,000. The Manufacturers Life Insurance Company boosted its holdings in Vericel by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,472 shares of the biotechnology company's stock valued at $1,215,000 after purchasing an additional 1,355 shares during the period. Finally, Algert Global LLC acquired a new position in shares of Vericel during the 2nd quarter worth approximately $213,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on VCEL. Truist Financial lifted their target price on Vericel from $61.00 to $67.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a report on Tuesday, December 24th. BTIG Research upped their price objective on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Stephens reiterated an "overweight" rating and set a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.